Here, we report the case of a patient who presented to our institution with severe, destructive, and un-reconstructable prosthetic valve endocarditis which required the planned implantation of a total artificial heart (TAH) to function as a bridge to cardiac transplantation.

COVID-19 has created challenges for society and the medical community. While the pandemic continues to unfold, the transplant community has had to pivot to keep recipients, donors, and transplant teams safe given these unprecedented times. This has resulted in a decrease in the number of transplants performed in the United States and an increased number of inactive patients on the UNOS waiting list.1 Waitlist and transplant recipients have an increased risk for acquiring COVID-19. It is speculated that this patient population is particularly vulnerable given their immunocompromised status and the high prevalence of comorbidities.2 Given the uncertainty surrounding the risk of transplant patients contracting COVID-19, there is interest in describing these cases in the literature.

A 52-year-old man presented to our institution with a one year history of intermittent, progressive chest tightness with activity. He underwent stress test which was positive. Coronary angiography revealed a long segment myocardial bridge of the left anterior descending artery (LAD). Initially, he was trialed on maximal medical therapy, however, symptoms continued. As a result, he was brought to the operating room for unroofing of the myocardial bridge with excellent clinical and radiographic outcome. The diagnosis, medical, and surgical management of myocardial bridge is complicated. Long-term data surrounding best options for management is scarce.